topic

782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors
Michael J Newman, Jeffery A Nieves, Gary B Gordon, Diana L Hanna, Angela T Alistar, Mohammed NAl Hallak, Roger J Waltzman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1815; DOI: 10.1136/jitc-2023-SITC2023.0782-E
Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway
Jing Zhang, Hui Dai, Lei Huo, Jared K Burks, Daniel J McGrail, Shiaw-Yih Lin

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007560; DOI: 10.1136/jitc-2023-007560
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O’Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007725; DOI: 10.1136/jitc-2023-007725
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
Caicun Zhou, Minu K Srivastava, Hao Xu, Enriqueta Felip, Heather Wakelee, Nasser Altorki, Martin Reck, Rüdiger Liersch, Anna Kryzhanivska, Satoshi Oizumi, Hiroshi Tanaka, John Hamm, Steven L McCune, Elizabeth Bennett, Barbara Gitlitz, Virginia McNally, Marcus Ballinger, Mark McCleland, Wei Zou, Meghna Das Thakur, Silvia Novello

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007047; DOI: 10.1136/jitc-2023-007047
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
Carla Faria, Fabien Gava, Pauline Gravelle, Juan Garcia Valero, Celia Dobaño-López, Nathalie Van Acker, Cathy Quelen, Gael Jalowicki, Renaud Morin, Cédric Rossi, Jean-Michel Lagarde, Jean-Jacques Fournié, Loïc Ysebaert, Camille Laurent, Patricia Pérez-Galán, Christine Bezombes

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007156; DOI: 10.1136/jitc-2023-007156
Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery
Bing Zhang, Michal Bassani-Sternberg

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007073; DOI: 10.1136/jitc-2023-007073
Multiplex imaging in immuno-oncology
Chen Zhao, Ronald N Germain

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e006923; DOI: 10.1136/jitc-2023-006923
Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
Patrick T Magahis, Steven B Maron, Darren Cowzer, Stephanie King, Mark Schattner, Yelena Janjigian, David Faleck, Monika Laszkowska

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007699; DOI: 10.1136/jitc-2023-007699
Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
Gerwin Gerhard Wemke Sandker, Jim Middelburg, Evienne Wilbrink, Janneke Molkenboer-Kuenen, Erik Aarntzen, Thorbald van Hall, Sandra Heskamp

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007596; DOI: 10.1136/jitc-2023-007596
FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
Nicolas Roussot, Julie Lecuelle, Lorraine Dalens, Caroline Truntzer, Francois Ghiringhelli

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007763; DOI: 10.1136/jitc-2023-007763

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages